MYH9 and breast cancer: Direct interaction between EIF6-224aa and the oncogene MYH9 in breast cancer inhibits the ubiquitin-proteasome pathway mediated activation of the Wnt/β-catenin pathway, thereby reducing the degradation of MYH9.42